ArticleWorld journal of gastrointestinal pharmacology and therapeutics2010
Diverticular disease: A therapeutic overview.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 35 citations in OpenAlex.
- Pylephlebitis: A Rare but Redoubtable Complication of Intra-Abdominal Infections-A Series of 15 Cases.Life (Basel, Switzerland) · 2025Article
- Suppurative Thrombosis of the Portal Vein (Pylephlebits): A Systematic Review of Literature.Journal of clinical medicine · 2022Review
- Effect of mesalazine combined with probiotics on inflammation and immune function of patients with inflammatory bowel disease.American journal of translational research · 2022Article
- Symptomatic uncomplicated diverticular disease management: an innovative food-grade formulation ofDrugs in context · 2020Article
- Role ofWorld journal of gastrointestinal pathophysiology · 2018Article
- Animal Models of Diverticulosis: Review and Recommendations.Digestive diseases and sciences · 2018Review
- Why perform colonoscopy following acute diverticulitis of the colon?Surgical endoscopy · 2014Article
- Efficacy, safety, and applicability of outpatient treatment for diverticulitis.Drug, healthcare and patient safety · 2014Review
- Advances in the management of colonic diverticulitis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2012Review
- Surgery for diverticulitis: a re-evaluation of the changing trends.International surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Formation of colonic diverticula, via herniation of the colonic wall, is responsible for the development of diverticulosis. When diverticulosis becomes symptomatic, it becomes diverticular disease. Diverticular disease is common in Western and industrialized countries, and it is associated with numerous abdominal symptoms (including pain, bloating, nausea, diarrhea, and constipation). Standard medical therapies with antibiotics are currently recommended for patients affected by diverticular disease. However, changing concepts on the pathophysiology of the disease suggest that diverticular disease may share many of the hallmarks of inflammatory bowel diseases. On this basis, the addition of therapies using mesalazine and probiotics may enhance treatment efficacy by shortening the course of the disease and preventing recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.